BIOCON, Author at Biocon

Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Mylan and Biocon Announce U.S. FDA Submission for Proposed Biosimilar Trastuzumab

Mylan and Biocon Announce Regulatory Submission for Insulin Glargine Accepted for Review by European Medicines Agency

Biocon Ranked Among Global Top Ten Biotech Employers; The only Asian Company to Feature in 2016 Rankings Biocon moves up to No. 9 from No. 13 last year

Biocon Q2 FY17 Revenue Up 21%; EBITDA Up 45%; Revenues at Rs 992 Crs.; EBITDA at Rs 277 Crs.; Net Profit at Rs 147 Crs.

Biocon Appoints Suresh Subramanian as Head of Branded Formulations (India) Business

Kiran Mazumdar Shaw Appointed ‘Knight of the Legion of Honour’ by the Government of France

Mylan & Biocon Announce Regulatory Submission for Proposed Biosimilar Pegfilgrastim Accepted for Review by European Medicines Agency

Biocon’s Insulin Glargine Launched in Japan

Biocon, Quark Announce Initiation of Pivotal Phase II/III Study of QPI-1007 in Rare Eye Disease in India

Mylan and Biocon to Present Phase 3 Trastuzumab Biosimilar Data at the American Society of Clinical Oncology (ASCO) Annual Meeting